Experts discuss the evolving role of checkpoint inhibition in patients with advanced bladder cancer.
This activity is intended for oncologists, urologists, and other healthcare professionals who treat patients with bladder cancer.
The goal of this activity is to discuss the role of immunotherapy, including how to determine eligibility and how to manage immune-related adverse events (irAEs), in the treatment of advanced bladder cancer.
Approximate Time to Complete: 30 minutes
Credit Available: Apr. 30, 2019- Apr. 30, 2020
Developed through a partnership between SITC and Medscape.